Phexa develops solutions for Gram-negative bacterial infections using Lysibody and Bacteriophage Therapy. This method, known as “recombinant immunotherapy,” utilizes special proteins to target infections like typhoid, tuberculosis, and sepsis. Phexa’s technology addresses antibiotic resistance, boosts immunity, and lowers healthcare costs. By offering affordable and accessible treatments developed locally, Phexa aims to improve health outcomes and reduce import expenses.